Research progress in targeted and immunotherapy for biliary tract cancer
10.3969/j.issn.1005-6483.20250643
- VernacularTitle:胆道癌靶向免疫治疗研究进展
- Author:
Lei NIE
1
;
Haiyan ZHANG
;
Jian SHEN
;
Dongde WU
Author Information
1. 430000 武汉,湖北省肿瘤医院肝胆胰外科
- Publication Type:Journal Article
- Keywords:
biliary tract cancer;
targeted therapy;
immunotherapy;
prognosis
- From:
Journal of Clinical Surgery
2025;33(7):775-778
- CountryChina
- Language:Chinese
-
Abstract:
Biliary tract cancer(BTC)due to its subtle early symptoms,approximately 60％-70％of patients are diagnosed at an advanced stage,limiting the effectiveness of treatment.While traditional treatment methods such as surgery and chemotherapy remain the primary approaches,their efficacy is limited by the heterogeneity of the disease and the development of resistance.Recently,targeted therapies and immunotherapy have emerged as promising strategies,showing good prospects in clinical trials.Targeted drugs addressing common genetic mutations in BTC,such as FGFR2 gene fusion,IDH1 mutations,and HER2 amplification,have shown some therapeutic efficacy.In addition,the combination of immune checkpoint inhibitors with chemotherapy has shown potential in prolonging survival.However,targeted and immunotherapy for BTC still faces challenges,and future research should focus on personalized treatment,combining genetic testing and immunotherapy to further optimize therapeutic strategies and improve patient quality of life.
